Lexaria Bioscience Corp. announced a registered direct offering priced at $1.315 per share.
The offering includes the sale of 2,661,600 shares of common stock.
Concurrent private placement will issue unregistered warrants with an exercise price of $1.19 per share.
Offering Details
$3.5 million aggregate gross proceeds from the offering.
Use of Proceeds
Intends to advance research, fund working capital, and general corporate purposes.
Warrants Issuance
Concurrent private placement issuing unregistered warrants for common stock.
- Lexaria aims to use proceeds to enhance research and development efforts.
- The offering demonstrates investor confidence in the company's drug delivery platforms.
The offering is a strategic step for Lexaria Bioscience Corp. to fund its growth and innovation in drug delivery platforms.